Table 3.

Association between SGLT2i, GLP1-RA, and DPP-4i use and risk of all-cause death within 30 days in patients with COVID-19

Model	SGLT2i no	SGLT2i yes	P-value	GLP1-RA no	GLP1-RA yes	P-value	DPP-4i no	DPP-4i yes	P-value
Matched, n (%) event	146 (16.9)	152 (17.6)		169 (20.8)	149 (18.3)		489 (31.7)	541 (35.1)
RR (95% CI)	ref	1.04 (0.85–1.27)	0.694	ref	0.88 (0.73–1.07)	0.201	ref	1.11 (1.00–1.22)	0.046
All patients, n (%) event	2823 (34.7)	152 (17.3)		2823 (34.5)	152 (18.2)		2432 (32.6)	543 (35.1)
Crude RR (95% CI)	ref	0.50 (0.43–0.58)	<0.001	ref	0.53 (0.46–0.61)	<0.001	ref	1.08 (1.00–1.16)	0.059
Adjusted RR (95% CI)	ref	0.91 (0.79–1.05)	0.183	ref	0.91 (0.79–1.04)	0.155	ref	1.05 (0.98–1.12)	0.202